The National Institute on Aging (NIA) is currently sponsoring a clinical trial to determine the effectiveness of the medication quinacrine on survival in sporadic Creutzfeldt-Jakob disease (sCJD). To access detailed information directly please visit http://www.clinicaltrials.gov/ct/show/NCT00183092.